Integra LifeSciences (IART) Stock Forecast, Price Target & Predictions
IART Stock Forecast
Integra LifeSciences stock forecast is as follows: an average price target of $23.00 (represents a 5.50% upside from IART’s last price of $21.80) and a rating consensus of 'Sell', based on 6 wall street analysts offering a 1-year stock forecast.
IART Price Target
The average price target for Integra LifeSciences (IART) is $23.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $20.00. This represents a potential 5.50% upside from IART's last price of $21.80.
IART Analyst Ratings
According to 6 Wall Street analysts, Integra LifeSciences's rating consensus is 'Sell'. The analyst rating breakdown for IART stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 1 'Hold' (16.67%), 3 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Integra LifeSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 07, 2024 | Ryan Zimmerman | BTIG | $20.00 | $17.43 | 14.74% | -8.26% |
| Jul 30, 2024 | Richard Newitter | Truist Financial | $26.00 | $24.59 | 5.73% | 19.27% |
| Jul 30, 2024 | Joanne Wuensch | Citigroup | $23.00 | $25.42 | -9.52% | 5.50% |
| Jul 29, 2024 | Ryan Zimmerman | BTIG | $22.00 | $25.42 | -13.45% | 0.92% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $32.00 | $29.84 | 7.24% | 46.79% |
| May 07, 2024 | Richard Newitter | Truist Financial | $25.00 | $23.14 | 8.04% | 14.68% |
| May 07, 2024 | David Turkaly | JMP Securities | $40.00 | $23.14 | 72.86% | 83.49% |
| May 06, 2024 | Vik Chopra | Wells Fargo | $25.00 | $23.14 | 8.04% | 14.68% |
| Oct 26, 2022 | Matt O'Brien | Piper Sandler | $50.00 | $46.85 | 6.72% | 129.36% |
| Jul 28, 2022 | FY22 EPS | Piper Sandler | $55.00 | $56.53 | -2.71% | 152.29% |
| May 20, 2021 | Anthony Petrone | Jefferies | $86.00 | $70.95 | 21.21% | 294.50% |
| Apr 29, 2021 | Shagun Singh Chadha | RBC Capital | $74.00 | $75.07 | -1.43% | 239.45% |
| Apr 29, 2021 | Larry Biegelsen | Wells Fargo | $74.00 | $75.07 | -1.43% | 239.45% |
The latest Integra LifeSciences stock forecast, released on Oct 07, 2024 by Ryan Zimmerman from BTIG, set a price target of $20.00, which represents a 14.74% increase from the stock price at the time of the forecast ($17.43), and a -8.26% decrease from IART last price ($21.80).
Integra LifeSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 8 |
| Avg Price Target | - | $20.00 | $26.63 |
| Last Closing Price | $21.80 | $21.80 | $21.80 |
| Upside/Downside | -100.00% | -8.26% | 22.16% |
In the current month, the average price target of Integra LifeSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Integra LifeSciences's last price of $21.80. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 04, 2024 | Citigroup | Sell | Sell | Hold |
| Jul 30, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jul 30, 2024 | Citigroup | Neutral | Sell | Downgrade |
| Jul 29, 2024 | BTIG | Sell | Negative | Downgrade |
| Jul 29, 2024 | BTIG | Sell | Downgrade | |
| Jul 15, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Jul 10, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 22, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 07, 2024 | Wells Fargo | Market Outperform | Market Outperform | Hold |
| May 07, 2024 | Truist Financial | Underperform | Underperform | Hold |
| May 07, 2024 | JMP Securities | Outperform | Outperform | Hold |
| May 07, 2024 | Oppenheimer | Perform | Downgrade | |
| May 07, 2024 | Bank of America Securities | Underperform | Underperform | Hold |
| May 06, 2024 | Wells Fargo | Market Outperform | Equal-Weight | Downgrade |
| Apr 03, 2024 | Citigroup | Neutral | Upgrade | |
| Feb 29, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Feb 29, 2024 | Wells Fargo | Market Outperform | Market Outperform | Hold |
| Dec 22, 2023 | Truist Financial | Underperform | Underperform | Hold |
| Dec 22, 2023 | Wells Fargo | Market Outperform | Market Outperform | Hold |
| Dec 05, 2023 | Wells Fargo | Overweight | Upgrade | |
| Jul 27, 2022 | Piper Sandler | Neutral | Neutral | Hold |
Integra LifeSciences's last stock rating was published by Citigroup on Nov 04, 2024. The company gave IART a "Sell" rating, the same as its previous rate.
Integra LifeSciences Financial Forecast
Integra LifeSciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $381.27M | $380.85M | $398.02M | $385.19M | $397.81M | $376.64M | $405.52M | $386.86M | $389.99M | $360.07M | $388.65M | $370.23M | $258.67M | $354.32M | $395.13M | $379.10M |
| Avg Forecast | $476.67M | $427.80M | $451.00M | $429.57M | $456.72M | $408.57M | $431.31M | $411.65M | $445.12M | $375.81M | $413.07M | $363.74M | $399.34M | $387.22M | $374.01M | $373.23M | $397.92M | $378.33M | $395.35M | $362.41M | $404.56M | $384.62M | $376.11M | $349.78M | $389.06M | $351.65M | $243.82M | $359.84M | $397.52M | $376.27M |
| High Forecast | $483.90M | $434.30M | $457.85M | $436.09M | $463.66M | $414.78M | $437.86M | $417.65M | $447.43M | $375.82M | $413.07M | $364.63M | $400.71M | $387.22M | $379.69M | $378.90M | $403.96M | $378.33M | $395.35M | $362.41M | $404.56M | $384.62M | $376.11M | $349.78M | $389.06M | $351.65M | $243.82M | $359.84M | $397.52M | $376.27M |
| Low Forecast | $469.96M | $421.78M | $444.66M | $423.53M | $450.30M | $402.83M | $425.24M | $408.35M | $442.66M | $375.81M | $413.07M | $362.85M | $397.66M | $387.22M | $368.75M | $367.98M | $392.33M | $378.33M | $395.35M | $362.41M | $404.56M | $384.62M | $376.11M | $349.78M | $389.06M | $351.65M | $243.82M | $359.84M | $397.52M | $376.27M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 8 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.00% | 1.02% | 1.01% | 1.04% | 1.00% | 1.01% | 1.04% | 1.03% | 1.00% | 1.05% | 1.06% | 0.98% | 0.99% | 1.01% |
Integra LifeSciences's average Quarter revenue forecast for Sep 23 based on 4 analysts is $387.22M, with a low forecast of $387.22M, and a high forecast of $387.22M. IART's average Quarter revenue forecast represents a 1.56% increase compared to the company's last Quarter revenue of $381.27M (Jun 23).
Integra LifeSciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 8 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.50M | $44.99M | $80.64M | $100.43M | $93.42M | $80.69M | $67.99M | $93.10M | $87.73M | $109.42M | $82.44M | $93.33M | $47.01M | $58.34M | $67.75M | $14.05M |
| Avg Forecast | $96.66M | $86.75M | $91.45M | $87.11M | $92.61M | $82.85M | $87.46M | $83.47M | $90.26M | $76.21M | $83.76M | $89.02M | $80.98M | $78.52M | $75.84M | $80.93M | $73.89M | $60.74M | $63.47M | $73.57M | $64.95M | $61.75M | $60.38M | $86.39M | $62.46M | $56.46M | $39.14M | $72.24M | $63.82M | $60.41M |
| High Forecast | $98.12M | $88.06M | $92.84M | $88.43M | $94.02M | $84.11M | $88.79M | $84.69M | $90.73M | $76.21M | $83.76M | $106.83M | $81.25M | $78.52M | $76.99M | $97.12M | $88.66M | $60.74M | $63.47M | $88.29M | $64.95M | $61.75M | $60.38M | $103.66M | $62.46M | $56.46M | $39.14M | $86.68M | $63.82M | $60.41M |
| Low Forecast | $95.30M | $85.53M | $90.17M | $85.88M | $91.31M | $81.68M | $86.23M | $82.80M | $89.76M | $76.20M | $83.76M | $71.22M | $80.64M | $78.52M | $74.77M | $64.75M | $59.11M | $60.74M | $63.47M | $58.86M | $64.95M | $61.75M | $60.38M | $69.11M | $62.46M | $56.46M | $39.14M | $57.79M | $63.82M | $60.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.16% | 0.56% | 1.09% | 1.65% | 1.47% | 1.10% | 1.05% | 1.51% | 1.45% | 1.27% | 1.32% | 1.65% | 1.20% | 0.81% | 1.06% | 0.23% |
4 analysts predict IART's average Quarter EBITDA for Sep 23 to be $78.52M, with a high of $78.52M and a low of $78.52M. This is 527.95% upper than Integra LifeSciences's previous annual EBITDA (Jun 23) of $12.50M.
Integra LifeSciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 8 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.18M | $24.23M | $52.95M | $49.91M | $44.79M | $32.90M | $45.38M | $43.23M | $35.07M | $45.39M | $92.74M | $32.34M | $-369.00K | $9.18M | $15.32M | $-27.61M |
| Avg Forecast | $66.26M | $51.98M | $50.97M | $47.14M | $59.85M | $42.05M | $46.09M | $42.99M | $65.31M | $29.82M | $47.66M | $36.30M | $69.03M | $59.50M | $43.52M | $33.00M | $49.32M | $55.75M | $61.87M | $30.00M | $65.08M | $56.08M | $50.99M | $35.84M | $56.73M | $42.01M | $6.95M | $11.37M | $51.67M | $50.65M |
| High Forecast | $67.56M | $53.01M | $51.97M | $48.07M | $61.03M | $42.88M | $47.00M | $46.17M | $66.85M | $29.82M | $47.68M | $43.56M | $70.39M | $59.52M | $44.38M | $39.60M | $59.19M | $55.75M | $61.87M | $36.00M | $65.08M | $56.08M | $50.99M | $43.00M | $56.73M | $42.01M | $6.95M | $13.64M | $51.67M | $50.65M |
| Low Forecast | $65.04M | $51.03M | $50.03M | $46.28M | $58.75M | $41.28M | $45.25M | $39.01M | $63.77M | $29.82M | $47.65M | $29.04M | $68.27M | $59.49M | $42.72M | $26.40M | $39.46M | $55.75M | $61.87M | $24.00M | $65.08M | $56.08M | $50.99M | $28.67M | $56.73M | $42.01M | $6.95M | $9.09M | $51.67M | $50.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.10% | 0.73% | 1.07% | 0.90% | 0.72% | 1.10% | 0.70% | 0.77% | 0.69% | 1.27% | 1.63% | 0.77% | -0.05% | 0.81% | 0.30% | -0.55% |
Integra LifeSciences's average Quarter net income forecast for Sep 23 is $59.50M, with a range of $59.49M to $59.52M. IART's average Quarter net income forecast represents a 1322.18% increase compared to the company's last Quarter net income of $4.18M (Jun 23).
Integra LifeSciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 8 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $164.91M | $166.66M | $151.92M | $143.82M | $160.65M | $159.93M | $162.25M | $156.01M | $162.55M | $156.63M | $162.39M | $150.08M | $116.11M | $165.95M | $174.25M | $173.10M |
| Avg Forecast | $198.28M | $177.95M | $187.60M | $178.69M | $189.98M | $169.95M | $179.41M | $171.23M | $185.16M | $156.33M | $171.82M | $176.44M | $166.11M | $161.07M | $155.58M | $160.40M | $176.32M | $158.30M | $165.42M | $145.81M | $169.28M | $160.94M | $157.37M | $123.66M | $162.79M | $147.14M | $102.02M | $205.46M | $166.33M | $157.44M |
| High Forecast | $201.29M | $180.65M | $190.45M | $181.40M | $192.87M | $172.53M | $182.14M | $173.73M | $186.12M | $156.33M | $171.82M | $211.72M | $166.68M | $161.07M | $157.94M | $192.48M | $211.59M | $158.30M | $165.42M | $174.98M | $169.28M | $160.94M | $157.37M | $148.39M | $162.79M | $147.14M | $102.02M | $246.56M | $166.33M | $157.44M |
| Low Forecast | $195.49M | $175.45M | $184.96M | $176.17M | $187.31M | $167.56M | $176.89M | $169.86M | $184.13M | $156.32M | $171.82M | $141.15M | $165.42M | $161.07M | $153.39M | $128.32M | $141.06M | $158.30M | $165.42M | $116.65M | $169.28M | $160.94M | $157.37M | $98.93M | $162.79M | $147.14M | $102.02M | $164.37M | $166.33M | $157.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 0.86% | 0.91% | 0.97% | 1.10% | 0.96% | 0.97% | 1.03% | 1.27% | 1.00% | 1.02% | 1.14% | 0.81% | 1.05% | 1.10% |
Integra LifeSciences's average Quarter SG&A projection for Sep 23 is $161.07M, based on 4 Wall Street analysts, with a range of $161.07M to $161.07M. The forecast indicates a -2.33% fall compared to IART last annual SG&A of $164.91M (Jun 23).
Integra LifeSciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 8 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.05 | $0.30 | $0.63 | $0.60 | $0.54 | $0.39 | $0.54 | $0.51 | $0.41 | $0.54 | $1.10 | $0.38 | $-0.00 | $0.11 | $0.18 | $-0.32 |
| Avg Forecast | $0.87 | $0.68 | $0.67 | $0.62 | $0.78 | $0.55 | $0.60 | $0.56 | $0.85 | $0.39 | $0.62 | $0.55 | $0.90 | $0.78 | $0.57 | $0.74 | $0.90 | $0.72 | $0.80 | $0.68 | $0.84 | $0.72 | $0.66 | $0.57 | $0.73 | $0.54 | $0.09 | $0.62 | $0.67 | $0.65 |
| High Forecast | $0.88 | $0.69 | $0.68 | $0.63 | $0.80 | $0.56 | $0.61 | $0.60 | $0.87 | $0.39 | $0.62 | $0.55 | $0.92 | $0.78 | $0.58 | $0.75 | $0.92 | $0.72 | $0.80 | $0.68 | $0.84 | $0.72 | $0.66 | $0.57 | $0.73 | $0.54 | $0.09 | $0.62 | $0.67 | $0.65 |
| Low Forecast | $0.85 | $0.67 | $0.65 | $0.61 | $0.77 | $0.54 | $0.59 | $0.51 | $0.83 | $0.39 | $0.62 | $0.55 | $0.89 | $0.78 | $0.56 | $0.72 | $0.89 | $0.72 | $0.80 | $0.68 | $0.84 | $0.72 | $0.66 | $0.57 | $0.73 | $0.54 | $0.09 | $0.62 | $0.67 | $0.65 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.09% | 0.41% | 0.70% | 0.83% | 0.68% | 0.57% | 0.64% | 0.70% | 0.63% | 0.95% | 1.50% | 0.71% | -0.05% | 0.18% | 0.27% | -0.49% |
According to 4 Wall Street analysts, Integra LifeSciences's projected average Quarter EPS for Sep 23 is $0.78, with a low estimate of $0.78 and a high estimate of $0.78. This represents a 1405.53% increase compared to IART previous annual EPS of $0.05 (Jun 23).